[{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chugai Pharmaceutical \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0.22,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ruzasvir","moa":"||Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Nephrology","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Bemnifosbuvir
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target